OPTUS Pharmaceutical Co., Ltd. (KOSDAQ:131030)

OPTUS Pharmaceutical Revenue

OPTUS Pharmaceutical had revenue of 24.64B KRW in the quarter ending June 30, 2026, with 13.07% growth. This brings the company's total for the last twelve months to 94.47B, up 14.08% year-over-year. In the year 2025, OPTUS Pharmaceutical had annual revenue of 87.16B with 6.42% growth. That makes OPTUS Pharmaceutical the 25,256th largest company in the world by revenue and 1,481st in South Korea.

• Revenue (ttm): 94.47B
• Revenue Growth: +14.08%
• P/S Ratio: 1.11
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 104.82B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

• Tearin Blood and Others 77.76B 94.9%
• Nexol Tablet and Others 2.94B 3.6%
• LDPE Scrap and Others 710.00M 0.9%
• Oesu Eye Cleaner and Others 496.00M 0.6%

By Geography

• South Korea 81.80B 99.9%
• Overseas 106.14M 0.1%

Fiscal year ended Dec 31, 2024 See the full OPTUS Pharmaceutical breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	87.16B	5.26B	6.42%
Dec 31, 2024	81.90B	9.48B	13.09%
Dec 31, 2023	72.43B	13.77B	23.47%
Dec 31, 2022	58.66B	1.34B	2.34%
Dec 31, 2021	57.32B	-3.51B	-5.77%

Data Source: S&P Global Market Intelligence Last updated: Jul 30, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 23, 2026

Data Sources Report a data error